Changes at one level of a hormonal system do not guarantee matching changes downstream. This small DSIP experiment provides a useful example. Primary study
What was studied
Eleven healthy men received DSIP and saline in a randomized, double-blind crossover study. Plasma ACTH-like immunoreactivity decreased after DSIP relative to the control condition. Plasma cortisol followed its usual daytime decline without a treatment difference. Urinary cortisol and monoamine-metabolite measures also did not differ. Primary report
Our appraisal: do not turn an ACTH result into a cortisol claim
A pathway is not a single measurement. Its components can have different timing, feedback, sensitivity, and measurement properties. A significant change in an upstream marker should not be described as a demonstrated downstream effect when the downstream measurement was neutral.
The assay wording deserves attention as well. Immunoreactivity describes recognition by an assay reagent. Understanding which molecular forms contribute to the signal is part of interpreting the result; the label should not be silently broadened into a complete account of secretion or biological activity.
The crossover design helps compare conditions within the same participants, but it does not make the small sample representative of everyone. Results in healthy men do not establish benefits for people with sleep disorders, stress-related symptoms, or endocrine disease.
This was also not a clinical stress-reduction experiment. A hormone measurement alone cannot show that participants felt better, slept better, or experienced improved daily functioning. Those outcomes require direct assessment.
The most defensible summary is therefore deliberately specific: an ACTH-related assay signal changed, while the reported cortisol measurements did not. That observation can motivate mechanistic research, but it does not validate marketing DSIP as a cortisol-lowering or stress-treatment intervention. The neutral findings are essential to the interpretation.
Frequently asked questions
How many men participated?
Eleven.
Was placebo comparison included?
Yes, using saline in a crossover design.
Which assay result changed?
Plasma ACTH-like immunoreactivity.
Did plasma cortisol change because of DSIP?
No treatment effect was detected.
Did urinary cortisol differ?
No.
Was improved sleep demonstrated here?
Not by these hormone results.
What claim should be avoided?
Calling this proof that DSIP lowers cortisol or treats stress.